Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1

  • End date
    Mar 31, 2025
  • participants needed
  • sponsor
    4SC AG
Updated on 31 October 2021
metastatic merkel cell carcinoma


This phase II trial studies how well domatinostat (4SC-202) works in combination with avelumab in adult patients with advanced unresectable and/or metastatic Merkel Cell Carcinoma that have progressed on a previous therapy with an anti-PD-(L)1 antibody

Condition Neuroendocrine Carcinoma, Neuroendocrine carcinoma, Merkel cell carcinoma
Treatment domatinostat in combination with avelumab
Clinical Study IdentifierNCT04393753
Sponsor4SC AG
Last Modified on31 October 2021


Yes No Not Sure

Inclusion Criteria

Histologically confirmed Merkel Cell Carcinoma (MCC)
ECOG performance status 1
MCC in an advanced, unresectable stage III or metastatic stage IV (includes patients who refused surgical resection or are not eligible for such surgical resection)
Progressing on previous anti-PD-(L)1 antibody monotherapy within the last 12 weeks before planned first administration of study medication

Exclusion Criteria

History of serious anti-PD-(L)1 therapy-related adverse reactions prohibiting further avelumab treatment
More than one line of previous systemic anti-neoplastic therapy other than anti-PD-(L)1 antibody monotherapy
Palliative radiation therapy of single lesions within 2 weeks before planned administration of study medication
Presence of significant active or chronic disease (infections, immunodeficiencies, cardiovascular, psychiatric disorders)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note